netFormulary Berkshire West NHS NHS
Royal Berkshire Foundation Trust
Berkshire Healthcare NHS Foundation Trust
Newbury and District CCG
North and West Reading CCG
South Reading CCG
Wokingham CCG
 
 Search
 Formulary Chapter 2: Cardiovascular system - Full Section
Notes:
This formulary is used by multiple organisations. There may be some instances where an item is on the formulary for one organisation but not the others. To help distinguish between each organisation, text will be colour coded, i.e. information relating to the Royal Berkshire NHS Foundation Trust will be in blue and Berkshire Healthcare NHS Foundation Trust will be in purple. Please ensure you read all information detailed under a drug.   
Numbers in brackets indicate counts of (Formulary items, Non Formulary items)
02.01 Positive inotropic drugs (0,0)
02.01.01 Cardiac glycosides (1,0)
Digoxin-specific antibody (0,0)
02.01.02 Phosphodiesterase type-3 inhibitors (0,2)
02.02 Diuretics (0,0)
02.02.01 Thiazides and related diuretics (5,0)
02.02.02 Loop diuretics (2,0)
02.02.03 Potassium-sparing diuretics and aldosterone antagonists (1,1)
Aldosterone antagonists (3,1)
02.02.04 Potassium-sparing diuretics with other diuretics (2,8)
02.02.05 Osmotic diuretics (1,0)
02.02.06 Mercurial diuretics (0,0)
02.02.07 Carbonic anhydrase inhibitors (0,0)
02.02.08 Diuretics with potassium (0,5)
02.03 Anti-arrhythmic drugs (0,0)
02.03.01 Management of arrhythmias (0,0)
02.03.02 Drugs for arrhythmias (0,1)
Supraventricular arrhythmias (2,0)
Supraventricular and ventricular arrhythmias (5,6)
Ventricular arrhythmias (1,1)
02.04 Beta-adrenoceptor blocking drugs (9,26)
02.05 Drugs affecting the renin-angiotensin system and some other antihypertensive drugs (0,0)
02.05.01 Vasodilator antihypertensive drugs (2,13)
02.05.02 Centrally acting antihypertensive drugs (3,2)
02.05.03 Adrenergic neurone blocking drugs (1,0)
02.05.04 Alpha-adrenoceptor blocking drugs (2,5)
Phaeochromocytoma (2,1)
02.05.05 Drugs affecting the renin-angiotensin system (0,1)
Heart Failure (1,0)
02.05.05.01 Angiotensin-converting enzyme inhibitors (ACE inhibitors) (6,23)
02.05.05.02 Angiotensin-II receptor antagonists (4,4)
02.05.05.03 Renin inhibitors (2,2)
02.06 Nitrates, calcium-channel blockers, and potassium-channel activators (0,0)
Angina (0,0)
02.06.01 Nitrates (2,36)
02.06.02 Calcium-channel blockers (16,35)
02.06.03 Other anitanginal drugs (3,0)
02.06.04 Peripheral vasodilators and related drugs (0,4)
Other preparations used in peripheral vascular disease (1,1)
02.07 Sympathomimetics (0,0)
02.07.01 Inotropic sympathomimetics (4,2)
02.07.02 Vasoconstrictor sympathomimetics (4,1)
02.07.03 Cardiopulmonary resuscitation (1,0)
02.08 Anticoagulants and protamine (0,0)
02.08.01 Parenteral anticoagulants (0,1)
Heparin (1,0)
Low molecular weight heparins (3,0)
Heparinoids (0,1)
Hirudins (1,1)
Heparin flushes (2,1)
Epoprostenol (1,0)
Fondaparinux (0,2)
02.08.02 Oral anticoagulants (6,1)
VTE prophylaxis in hip/knee surgery (0,0)
02.08.03 Protamine sulphate (1,1)
02.09 Antiplatelet drugs (8,9)
02.10 Stable angina, acute coronary syndromes, and fibrinolysis (0,0)
02.10.01 Management of stable angina and acute coronary syndromes (0,0)
02.10.02 Fibrinolytic drugs (4,4)
02.11 Antifibrinolytic drugs and haemostatics (2,2)
Blood-related products (0,9)
02.12 Lipid-regulating drugs (0,1)
Bile acid sequestrants (1,4)
Ezetimibe (1,0)
Fibrates (1,8)
Statins (3,6)
Nicotinic acid group (0,3)
Omega-3 fatty acid compounds (0,2)
02.13 Local sclerosants (2,0)
02.14 PCSK9 Inhibitors (2,0)
netFormulary